Asset Details
Do you wish to reserve the book?
Regulatory mechanisms of tau protein fibrillation under the conditions of liquid–liquid phase separation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Regulatory mechanisms of tau protein fibrillation under the conditions of liquid–liquid phase separation
Do you wish to request the book?
Regulatory mechanisms of tau protein fibrillation under the conditions of liquid–liquid phase separation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Regulatory mechanisms of tau protein fibrillation under the conditions of liquid–liquid phase separation
2020
Overview
One of the hallmarks of Alzheimer’s disease and several other neurodegenerative disorders is the aggregation of tau protein into fibrillar structures. Building on recent reports that tau readily undergoes liquid–liquid phase separation (LLPS), here we explored the relationship between disease-related mutations, LLPS, and tau fibrillation. Our data demonstrate that, in contrast to previous suggestions, pathogenic mutations within the pseudorepeat region do not affect tau441’s propensity to form liquid droplets. LLPS does, however, greatly accelerate formation of fibrillar aggregates, and this effect is especially dramatic for tau441 variants with disease-related mutations. Most important, this study also reveals a previously unrecognized mechanism by which LLPS can regulate the rate of fibrillation in mixtures containing tau isoforms with different aggregation propensities. This regulation results from unique properties of proteins under LLPS conditions, where total concentration of all tau variants in the condensed phase is constant. Therefore, the presence of increasing proportions of the slowly aggregating tau isoform gradually lowers the concentration of the isoform with high aggregation propensity, reducing the rate of its fibrillation. This regulatory mechanism may be of direct relevance to phenotypic variability of tauopathies, as the ratios of fast and slowly aggregating tau isoforms in brain varies substantially in different diseases.
Publisher
National Academy of Sciences
Subject
/ Alternative Splicing - genetics
/ Alzheimer Disease - genetics
/ Alzheimer Disease - pathology
/ Biophysics and Computational Biology
/ Humans
/ Isoforms
/ Mutation
/ Protein Aggregation, Pathological - genetics
/ Protein Aggregation, Pathological - pathology
/ Protein Isoforms - chemistry
/ Protein Isoforms - isolation & purification
/ Protein Isoforms - metabolism
/ Proteins
/ Recombinant Proteins - chemistry
/ Recombinant Proteins - genetics
/ Recombinant Proteins - isolation & purification
/ Recombinant Proteins - metabolism
/ Regulatory mechanisms (biology)
